DiamiR is a molecular diagnostics company focused on developing blood-based tests for early, including presymptomatic, detection, differential diagnosis, and monitoring of brain health conditions. The proprietary technology is based on targeted selection and quantitative analysis of circulating brain-enriched and inflammation-associated microRNA biomarkers in plasma. Our lead assay, CogniMIR(TM), is being developed for early detection of synaptic loss and neurodegeneration associated with Alzheimer’s disease to support more effective screening and enrollment of better characterized participants into clinical trials. Additional applications include prediction of progression (“progressors” vs “non-progressors”), detection of co-morbidities, treatment monitoring, and screening of broader populations. DiamiR collaborates with leading academic and clinical centers, disease foundations, and life sciences companies.